• Transactions
  • News
  • Events
  • Contact
  • SVB.com
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer

SVB Securities

Helping our clients move healthcare and technology forward

  • Firm
    • About
    • Careers
    • News
  • Expertise
    • Healthcare Investment Banking
    • Tech Investment Banking
    • Equity Capital Markets
    • Equity Research
    • Institutional Equities
    • Corporate Access
    • SVB MEDACorp
  • Sectors
    • Healthcare
    • Biopharma
    • Digital Health & HealthTech
    • Healthcare Services
    • Medical Devices
    • Tools & Diagnostics
    • Technology
    • Consumer Internet, Commerce Enablement & Marketing Software
    • Digital Infrastructure and Tech-Enabled Services
    • Education Technology
    • Enterprise Software
    • Industrial Technology
    • FinTech
  • Log in
  • Transactions
  • News
  • Events
  • Contact
  • SVB.com
January 2022

SVB Securities Continues to Strengthen Healthcare Equity Research Practice with Hire of David Risinger

Boston, MA – January 4, 2022 – SVB Securities, a leading investment bank serving the innovation economy, announced today that David Risinger, CFA, has joined the firm’s healthcare equity research team covering biopharmaceutical companies.

David joins SVB Securities as a Senior Managing Director reporting to Director of Research, Jim Kelly. David’s most recent Wall Street role was the Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to that, David held roles at Merrill Lynch & Co. and Dillon, Read & Co.

“David is a strong addition to SVB Securities, building upon our leadership across the healthcare industry,” said Jim Kelly. “His wealth of expertise covering the biopharma industry and his depth of relationships will serve to elevate our offerings for our clients and partners.”

Risinger stated: “I am excited to join SVB Securities to continue to develop its offering in biopharma research. This is a tremendous opportunity to work with a talented team that has proven its leadership in healthcare equity research and its commitment to producing a deep and differentiated research product for its clients.”

Reader Interactions

More in News

SVB Securities Expands Technology Equity Trading with the Addition of Amy Champion

August 2022

SVB Securities Continues Expansion of its Technology Equity Research Team with the Addition of Jackson Ader

July 2022

SVB Securities Hires Sterling Auty to Growing Technology Equity Research Team

July 2022

Partner With Us

We deliver a complete suite of capital market and advisory solutions to help our clients define and achieve their strategic, capital market, and investment objectives.

Contact Us

Footer

Firm

  • About
  • Careers
  • Events
  • Terms of Use
  • Member FINRA/SIPC, www.finra.org
  • Privacy Notice
  • Notice to California residents
  • Important Disclosures

Expertise

  • Healthcare Investment Banking
  • Tech Investment Banking
  • Capital Markets
  • M&A Advisory
  • Institutional Equities
  • Equity Research
  • SVB MEDACorp

Sectors

  • Biopharma
  • Medical Devices
  • Tools & Diagnostics
  • Healthcare Services
  • Consumer Internet, Commerce Enablement & Marketing Software
  • Digital Infrastructure and Tech-Enabled Services
  • Education Technology
  • Enterprise Software
  • Industrial Technology
  • FinTech

Other

  • News
  • Transactions
  • Contact
  • SVB.com
An SVB Company